Glial reactions in Parkinson's disease

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · see citing works

Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo

Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827 · see citing works

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis

Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914 · see citing works

Inflammation and Alzheimer’s disease

Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514 · see citing works

α-Synuclein Locus Triplication Causes Parkinson's Disease

Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · see citing works

GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons

Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206 · see citing works

α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies

Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 3,151 · see citing works

Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · see citing works

Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration

Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144 · see citing works

Oxidative stress in Parkinson's disease

Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053 · see citing works

α-synuclein locus duplication as a cause of familial Parkinson's disease

Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029 · see citing works

The many faces of macrophage activation

Mosser, D. M. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0602325 · Cited by 1,902 · see citing works

Control of microglial neurotoxicity by the fractalkine receptor

Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531 · see citing works

Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease

Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · see citing works

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease

Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · see citing works

Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease

Ibáñez, P., Bonnet, A. M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., & Pollak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17104-3 · Cited by 1,042 · see citing works

Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia

Kim, W., Mohney, R. P., Wilson, B. C., Jeohn, G., Liu, B., & Hong, J. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06309.2000 · Cited by 881 · see citing works

Microglial activation and dopamine terminal loss in early Parkinson's disease

Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 846 · see citing works

Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains

Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791 · see citing works

Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease

Kim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655 · see citing works

Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease

Chen, H., Zhang, S. M., Hernán, M. Á., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 633 · see citing works

Inflammation and neurodegeneration in Parkinson's disease

McGeer, P. L., & McGeer, E. G. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.005 · Cited by 628 · see citing works

NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies

McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498 · see citing works

ASTROCYTIC NEUROTRANSMITTER RECEPTORS IN SITU AND IN VIVO

Porter, J. T., & McCarthy, K. D. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00068-8 · Cited by 498 · see citing works

Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease

Chen, H., Jacobs, E. J., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 472 · see citing works

The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease

Bandopadhyay, R. (2004) · Brain · doi:10.1093/brain/awh054 · Cited by 466 · see citing works

NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains

Wakabayashi, K., Hayashi, S., Yoshimoto, M., Kudo, H., & Takahashi, H. (2000) · Acta Neuropathologica · doi:10.1007/pl00007400 · Cited by 439 · see citing works

Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons

Gao, H., Hong, J., Zhang, W., & Liu, B. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-03-00782.2002 · Cited by 439 · see citing works

Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition

Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-14 · Cited by 414 · see citing works

Inflammatory Process in Parkinsons Disease: Role for Cytokines

Nagatsu, T., & Sawada, M. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381620 · Cited by 412 · see citing works

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407 · see citing works

Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging

Cicchetti, F., Brownell, A., Williams, K. S., Chen, Y. I., Livni, E., & Ole Isacson, A. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406 · see citing works

Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration

McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400 · see citing works

Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease

Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., & O'Callaghan, J. P. (2002) · The FASEB Journal · doi:10.1096/fj.02-0216fje · Cited by 364 · see citing works

Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation

Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 363 · see citing works

Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease

McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., & Tansey, M. G. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1504-06.2006 · Cited by 355 · see citing works

MANF: A New Mesencephalic, Astrocyte-Derived Neurotrophic Factor with Selectivity for Dopaminergic Neurons

Petrova, P. S., Raibekas, A. A., Pevsner, J., Vigo, N. T., Anafi, M., Moore, M. K., Peaire, A. E., Shridhar, V., Smith, D. I., Kelly, J., et al. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:2:173 · Cited by 353 · see citing works

Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes

Chen, P.-S., Peng, G.-S., Li, G., Yang, S., Wu, X., Wang, C. C., Wilson, B. C., Lu, R.-B., Gean, P.-W., Chuang, D.-M., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001893 · Cited by 352 · see citing works

Critical Role for Microglial NADPH Oxidase in Rotenone-Induced Degeneration of Dopaminergic Neurons

Gao, H., Liu, B., & Hong, J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06181.2003 · Cited by 338 · see citing works

Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease

Wilms, H., Rosenstiel, P. C., Sievers, J., Deuschl, G., Zecca, L., & Lucius, R. (2003) · The FASEB Journal · doi:10.1096/fj.02-0314fje · Cited by 337 · see citing works

Role of cytokines in inflammatory process in Parkinson’s disease

Sawada, M., Imamura, K., & Nagatsu, T. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_57 · Cited by 331 · see citing works

The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease

Mirza, B., Hadberg, H., Thomsen, P., & Moos, T. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00455-8 · Cited by 327 · see citing works

Selective microglial activation in the rat rotenone model of Parkinson's disease

Sherer, T., Betarbet, R. S., Kim, J.-H., & Greenamyre, J. T. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00172-1 · Cited by 317 · see citing works

Involvement of Interferon-γ in Microglial-Mediated Loss of Dopaminergic Neurons

Mount, M. P., Lira, A., Grimes, D., Smith, P. D., Faucher, S., Slack, R. S., Anisman, H., Hayley, S. P., & Park, D. S. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5321-06.2007 · Cited by 316 · see citing works

Neuroinflammatory processes in Parkinson's disease

Hirsch, É. C., Hunot, S., & Hartmann, A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.013 · Cited by 298 · see citing works

The expression and function of chemokines involved in CNS inflammation

Ubogu, E. E., Cossoy, M. B., & Ransohoff, R. M. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.002 · Cited by 277 · see citing works

Microglial Activation and Dopaminergic Cell Injury: AnIn VitroModel Relevant to Parkinson's Disease

Le, W. D., Rowe, D. B., Xie, W., Ortiz, I., He, Y., & Appel, S. H. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08447.2001 · Cited by 274 · see citing works

Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys

Judith Miklossy, A., Doudet, D., Schwab, C., Yu, S. Y., McGeer, E. G., & McGeer, P. L. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.034 · Cited by 255 · see citing works

Nrf2-mediated protection against 6-hydroxydopamine

Jakel, R. J., Townsend, J. A., Kraft, A. D., & Johnson, J. A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.01.131 · Cited by 252 · see citing works

Synergistic Dopaminergic Neurotoxicity of the Pesticide Rotenone and Inflammogen Lipopolysaccharide: Relevance to the Etiology of Parkinson's Disease

Gao, H., Hong, J., Zhang, W., & Liu, B. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01228.2003 · Cited by 251 · see citing works

Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration.

Iravani, M. M., Kashefi, K., Mander, P., Rose, S., & Jenner, P. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00562-0 · Cited by 247 · see citing works

Dopamine and noradrenaline control distinct functions in rodent microglial cells

Färber, K., Pannasch, U., & Kettenmann, H. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.01.003 · Cited by 238 · see citing works

Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease

Depino, A. M., Earl, C. D., Kaczmarczyk, E., Ferrari, C. C., Besedovsky, H. O., del Rey, A., Pitossi, F. J., & Oertel, W. H. (2003) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2003.03014.x · Cited by 237 · see citing works

Non-steroidal anti-inflammatory drugs in Parkinson's disease

Esposito, E., Matteo, V. D., Benigno, A., Pierucci, M., Crescimanno, G., & Giovanni, G. D. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.02.008 · Cited by 232 · see citing works

Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins

Yamada, T., McGeer, P. L., & McGeer, E. G. (1992) · Acta Neuropathologica · doi:10.1007/bf00427222 · Cited by 231 · see citing works

Chapter 36: Astrocytes and Parkinson's disease

Forno, L. S., DeLanney, L. E., Irwin, I., Monte, D. A. D., & Langston, J. W. (1992) · Progress in brain research · doi:10.1016/s0079-6123(08)61770-7 · Cited by 230 · see citing works

α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia

Klegeris, A., Pelech, S., Giasson, B. I., Maguire, J., Zhang, H., McGeer, E. G., & McGeer, P. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.013 · Cited by 227 · see citing works

The solubility of α‐synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease

Campbell, B. C. V., McLean, C., Culvenor, J. G., Gai, W., Blumbergs, P. C., Jäkälä, P., Beyreuther, K. T., Masters, C. L., & Li, Q. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00021.x · Cited by 221 · see citing works

Effects of norepinephrine on rat cultured microglial cells that express α1, α2, β1 and β2 adrenergic receptors

Mori, K., Ozaki, E., Zhang, B., Yang, L., Yokoyama, A., Takeda, I., Maeda, N., Sakanaka, M., & Tanaka, J. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00211-3 · Cited by 215 · see citing works

Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure

Barcia, C., Sánchez-Bahíllo, A., Fernández‐Villalba, E., Bautista‐Hernández, V., Poza, M., Fernández-Barreiro, A., Hirsch, É. C., & Herrero, M. T. (2004) · Glia · doi:10.1002/glia.20015 · Cited by 206 · see citing works

Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration.

Arimoto, T., & Bing, G. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(02)00017-7 · Cited by 202 · see citing works

A pivotal role of matrix metalloproteinase‐3 activity in dopaminergic neuronal degeneration via microglial activation

Kim, Y. S., Choi, D. H., Block, M. L., Lorenzl, S., Yang, L., Kim, Y., Sugama, S., Cho, B. P., Hwang, O., Browne, S. E., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-5865com · Cited by 199 · see citing works

LRRK2 Expression in Normal and Pathologic Human Brain and in Human Cell Lines

Judith Miklossy, A., Arai, T., Guo, J., Klegeris, A., Yu, S. Y., McGeer, E. G., & McGeer, P. L. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000235121.98052.54 · Cited by 183 · see citing works

To be or not to be (inflamed)—is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?

Marchetti, B., & Abbracchio, M. P. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.08.007 · Cited by 175 · see citing works

Microglial PHOX and Mac‐1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha‐synuclein

Zhang, W., Dallas, S., Zhang, D., Guo, J., Pang, H., Wilson, B. C., Miller, D. S., Chen, B., Zhang, W., McGeer, P. L., et al. (2007) · Glia · doi:10.1002/glia.20532 · Cited by 161 · see citing works

Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline

Casarejos, M. J., Menéndez, J., Solano, R. M., Rodríguez‐Navarro, J. A., de Yébenes, J. G., & Mena, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03777.x · Cited by 156 · see citing works

Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice

Sugama, S., Yang, L., Cho, B. P., DeGiorgio, L. A., Lorenzl, S., Albers, D. S., Beal, M. F., Volpe, B. T., & Joh, T. H. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04085-4 · Cited by 153 · see citing works

α-Synuclein Expression Modulates Microglial Activation Phenotype

Austin, S. A., Floden, A. M., Murphy, E. J., & Combs, C. K. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1799-06.2006 · Cited by 142 · see citing works

Free radicals in Parkinson's disease

Koutsilieri, E., Scheller, C., Grünblatt, E., Keinosuke, N. A. R. A., Li, J., & Riederer, P. F. (2002) · Journal of Neurology · doi:10.1007/s00415-002-1201-7 · Cited by 117 · see citing works

Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors

Keyser, J. D., Wilczak, N., Leta, R., & Streetland, C. (1999) · Neurology · doi:10.1212/wnl.53.8.1628 · Cited by 114 · see citing works

Upregulation of Protease-Activated Receptor-1 in Astrocytes in Parkinson Disease: Astrocyte-Mediated Neuroprotection Through Increased Levels of Glutathione Peroxidase

Ishida, Y., Nagai, A., Kobayashi, S., & Kim, S. U. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000195941.48033.eb · Cited by 109 · see citing works

Existence of functional β1‐ and β2‐adrenergic receptors on microglia

Tanaka, K. F., Kashima, H., Suzuki, H., Ono, K., & Sawada, M. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10399 · Cited by 105 · see citing works

Chromogranin A Induces a Neurotoxic Phenotype in Brain Microglial Cells

Ciesielski-Treska, J., Ulrich, G., Taupenot, L., Chasserot‐Golaz, S., Corti, A., Aunis, D., & Bader, M. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14339 · Cited by 101 · see citing works

The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity

Noelker, C., Bacher, M., Gocke, P., Wei, X., Klockgether, T., Du, Y., & Dodel, R. C. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.04.023 · Cited by 100 · see citing works

Reactive Macrophages Increase Oxidative Stress and Alpha-Synuclein Nitration During Death of Dopaminergic Neuronal Cells in Co-Culture: Relevance to Parkinson’s Disease

Shaik, S., Combs, C. K., & Ebadi, M. (2006) · Neurochemical Research · doi:10.1007/s11064-005-9233-x · Cited by 99 · see citing works

Role of Fcγ Receptors in Nigral Cell Injury Induced by Parkinson Disease Immunoglobulin Injection into Mouse Substantia Nigra

He, Y., Le, W., & Appel, S. H. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7946 · Cited by 97 · see citing works

Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage

Li, G., Cui, G., Tzeng, N., Wei, S., Wang, T., Block, M. L., & Hong, J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2555com · Cited by 97 · see citing works

Dopamine-derived Dopaminochrome Promotes H2O2 Release at Mitochondrial Complex I

Zoccarato, F., Toscano, P., & Alexandre, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500657200 · Cited by 95 · see citing works

Thrombin‐activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: Dual roles of mitogen‐activated protein kinase signaling pathways

Lee, D. Y., Oh, Y. J., & Jin, B. K. (2005) · Glia · doi:10.1002/glia.20190 · Cited by 88 · see citing works

CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system.

Chen, K., Huang, J., Gong, W., Zhang, L., Yu, P., & Wang, J. M. (2006) · PubMed · Cited by 77 · see citing works

3‐Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP‐elicited damage both in vivo and in vitro

Zhang, W., Shin, E., Wang, T., Lee, P. H., Pang, H., Wie, M., Kim, W., Kim, S., Huang, W., Wang, Y., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6006com · Cited by 76 · see citing works

Parkinson's disease and inflammatory changes

Barcia, C., Barreiro, A. F., Poza, M., & Herrero, M. T. (2003) · Neurotoxicity Research · doi:10.1007/bf03033170 · Cited by 76 · see citing works

Chemokines in the MPTP model of Parkinson’s disease: Absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration

Kalkonde, Y. V., MORGAN, W. W., Sigala, J. A., Maffi, S. K., Condello, C., Kuziel, W. A., Ahuja, S. S., & Ahuja, S. K. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.041 · Cited by 75 · see citing works

Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells

Klegeris, A., & McGeer, P. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.127 · Cited by 73 · see citing works

3‐Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS‐induced neurotoxicity

Zhang, W., Qin, L., Wang, T., Wei, S., Gao, H., Liu, J., Wilson, B. C., Liu, B., Zhang, W., Kim, H., et al. (2004) · The FASEB Journal · doi:10.1096/fj.04-1586fje · Cited by 70 · see citing works

Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra

Knott, C., Stern, G. M., Kingsbury, A. E., Welcher, A. A., & Wilkin, G. P. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00008-1 · Cited by 68 · see citing works

Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants

Klegeris, A., & McGeer, P. L. (1994) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)90067-1 · Cited by 68 · see citing works

Trisialoganglioside GT1b induces in vivo degeneration of nigral dopaminergic neurons: Role of microglia

Ryu, J. K., Shin, W. H., Kim, J., Joe, E. H., Lee, Y. B., Cho, K. G., Oh, Y. J., Kim, S. U., & Jin, B. K. (2002) · Glia · doi:10.1002/glia.10047 · Cited by 61 · see citing works

Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: Role of neuron–glia crosstalk

Saavedra, A., Baltazar, G., Rodrigues‐Santos, P., Carvalho, C. M., & Duarte, E. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.008 · Cited by 61 · see citing works

A Synthetic Derivative of the Natural Product Rocaglaol Is a Potent Inhibitor of Cytokine-Mediated Signaling and Shows Neuroprotective Activity in Vitro and in Animal Models of Parkinson’s Disease and Traumatic Brain Injury

Fahrig, T., Gerlach, I., & Horváth, E. J. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008177 · Cited by 59 · see citing works

Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases

Yasuhara, O., Kawamata, T., Aimi, Y., McGeer, E. G., & McGeer, P. L. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90227-5 · Cited by 58 · see citing works

Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity

McLaughlin, P., Zhou, Y., Ma, T., Liu, J., Zhang, W., Hong, J., Kovacs, M., & Zhang, J. (2006) · Glia · doi:10.1002/glia.20294 · Cited by 55 · see citing works

Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase‐2 via CD40: Relevance to Parkinson's disease

Okuno, T., Nakatsuji, Y., Kumanogoh, A., Moriya, M., Ichinose, H., Sumi, H., Fujimura, H., Kikutani, H., & Sakoda, S. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20599 · Cited by 54 · see citing works

Parkinson disease IgG and C5a-induced synergistic dopaminergic neurotoxicity: Role of microglia

Wang, X., Yan, Z.-Q., Lü, G., Stuart, S., & Chen, S. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.07.014 · Cited by 52 · see citing works

Amyloid β and neuromelanin—Toxic or protective molecules?The cellular context makes the difference

Rao, K. S. J., Hegde, M. L., Anitha, S., Musicco, M., Zucca, F. A., TURRO, N. J., & Zecca, L. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.03.004 · Cited by 49 · see citing works

Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates

Hayley, S. P., & Anisman, H. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381611 · Cited by 38 · see citing works

Reactive microgliosis participates in MPP + ‐induced dopaminergic neurodegeneration: role of 67 kDa laminin receptor

Wang, T., Zhang, W., Pei, Z., Block, M. L., Wilson, B. C., Reece, J. M., Miller, D. S., & Hong, J. (2006) · The FASEB Journal · doi:10.1096/fj.05-5053com · Cited by 36 · see citing works

Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(−)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease

Kato, H. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00411-2 · Cited by 33 · see citing works

Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: Implications in Parkinson's disease

Jana, S., Maiti, A. K., Bagh, M. B., Banerjee, K., Das, A., Roy, A., & Chakrabarti, S. (2007) · Brain Research · doi:10.1016/j.brainres.2006.09.100 · Cited by 33 · see citing works

Some Immunohistochemical Features of Argyrophilic Grain Dementia With Normal Cortical Choline Acetyltransferase Levels but Extensive Subcortical Pathology and Markedly Reduced Dopamine

Yamada, T., McGeer, P. L., & McGeer, E. G. (1992) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/002383099200500102 · Cited by 31 · see citing works

Relationship of Complement-Activated Oligodendrocytes to Reactive Microglia and Neuronal Pathology in Neurodegenerative Disease

Yamada, T., McGeer, P. L., & McGeer, E. G. (1991) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000107179 · Cited by 28 · see citing works

Anti-inflammatory activity of pergolide, a dopamine receptor agonist.

Bendele, A. M., Spaethe, S. M., Benslay, D. N., & Bryant, H. U. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20353-6 · Cited by 27 · see citing works

GT1b ganglioside induces death of dopaminergic neurons in rat mesencephalic cultures

Chung, E. S., Joe, E. H., Ryu, J. K., Kim, J., Lee, Y. B., Cho, K. G., Oh, Y. J., Maeng, S. H., Baik, H. H., Kim, S. U., et al. (2001) · Neuroreport · doi:10.1097/00001756-200103050-00036 · Cited by 24 · see citing works

Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons

Aimi, Y., & McGeer, P. L. (1996) · Parkinsonism & Related Disorders · doi:10.1016/1353-8020(96)00004-1 · Cited by 16 · see citing works

The involvement of glial cell-derived reactive oxygen and nitrogen species in Alzheimer’s disease

Walker, D. G., Lue, L., Klegeris, A., & McGeer, P. L. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8350-4_9 · Cited by 4 · see citing works

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1 · see citing works

Astrocytes: Biology and pathology

Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196 · see citing works

Mechanisms underlying inflammation in neurodegeneration

Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580 · see citing works

Hallmarks of neurodegenerative diseases

Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789 · see citing works

Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets

Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616 · see citing works

Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria

Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972 · see citing works

A Nurr1/CoREST Pathway in Microglia and Astrocytes Protects Dopaminergic Neurons from Inflammation-Induced Death

Saijo, K., Winner, B., Carson, C. T., Collier, J. G., Boyer, L. F., Rosenfeld, M. G., Gage, F. H., & Glass, C. K. (2009) · Cell · doi:10.1016/j.cell.2009.01.038 · Cited by 940 · see citing works

Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies

Lee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877 · see citing works

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy

Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859 · see citing works

Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population‐Based Study

BIGAL, M. E., Serrano, D., Buse, D. C., Scher, I., Stewart, W. F., & Lipton, R. B. (2008) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2008.01217.x · Cited by 848 · see citing works

Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease

Hamza, T. H., Zabetian, C. P., Tenesa, A., Laederach, A., Montimurro, J. S., Yearout, D., Kay, D. M., Doheny, K. F., Paschall, J. E., Pugh, E., et al. (2010) · Nature Genetics · doi:10.1038/ng.642 · Cited by 784 · see citing works

Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications

Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779 · see citing works

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

Duty, S., & Jenner, P. G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 758 · see citing works

Alternatively activated microglia and macrophages in the central nervous system

Franco, R., & Fernández‐Suárez, D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.003 · Cited by 650 · see citing works

Colonic inflammation in Parkinson's disease

Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., Bruley des Varannes, S., Naveilhan, P., Nguyen, J.-M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.007 · Cited by 627 · see citing works

Basic mechanisms of neurodegeneration: a critical update

Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 608 · see citing works

Sex differences in Parkinson’s disease

Gillies, G. E., Pienaar, I. S., Vohra, S., & Qamhawi, Z. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.02.002 · Cited by 495 · see citing works

Neuropeptide substance P and the immune response

Mashaghi, A., Marmalidou, A., Tehrani, M., Grace, P. M., Pothoulakis, C., & Dana, R. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2293-z · Cited by 493 · see citing works

Astrocytes in Alzheimer's Disease

Verkhratsky, A., Olabarria, M., Noristani, H. N., Yeh, C., & Rodriguez, J. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.017 · Cited by 453 · see citing works

Parkinson’s Disease

Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire‐Zeiss, K. A. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 442 · see citing works

Glia: Initiators and progressors of pathology in Parkinson's disease

Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 423 · see citing works

Targeted Overexpression of Human α-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease

Theodore, S., Cao, S., McLean, P. J., & Standaert, D. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e5e99 · Cited by 367 · see citing works

Astrocytic expression of Parkinson's disease-related A53T α-synuclein causes neurodegeneration in mice

Gu, X., Long, C.-X., Sun, L., Xie, C., Lin, X. Z., & Cai, H. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-12 · Cited by 341 · see citing works

Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review)

Guo, J., Zhao, X., Li, Y., Li, G., & Liu, X. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3406 · Cited by 347 · see citing works

The Role of Inflammatory and Oxidative Stress Mechanisms in the Pathogenesis of Parkinson’s Disease: Focus on Astrocytes

Niranjan, R. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8483-x · Cited by 331 · see citing works

Microglial pathology

Streit, W. J., Xue, Q.-S., Tischer, J., & Bechmann, I. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0142-6 · Cited by 317 · see citing works

CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s Disease

Saunders, J. A. H., Estes, K. A., Kosloski, L. M., Allen, H. E., Dempsey, K., Torres-Russotto, D., Meza, J., Santamaria, P., Bertoni, J., Murman, D., et al. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9402-z · Cited by 308 · see citing works

The Genetics of Parkinson Disease

Bekris, L. M., Mata, I. F., & Zabetian, C. P. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383572 · Cited by 307 · see citing works

Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders

Daniele, S. G., Béraud, D., Davenport, C., Cheng, K., Yin, H., & Maguire-Zeiss, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.2005965 · Cited by 303 · see citing works

Neuroglia in neurodegeneration

Heneka, M. T., Rodriguez, J. J., & Verkhratsky, A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.11.004 · Cited by 303 · see citing works

The influence of microglia on the pathogenesis of Parkinson's disease

Long-Smith, C. M., Sullivan, A. M., & Nolan, Y. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.08.001 · Cited by 296 · see citing works

Astrocytes as a Source for Extracellular Matrix Molecules and Cytokines

Wiese, S., Karus, M., & Faissner, A. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00120 · Cited by 262 · see citing works

Neuropathology of non-motor features of Parkinson disease

Dickson, D. W., Fujishiro, H., Orr, C., DelleDonne, A., Josephs, K. A., Frigerio, R., Burnett, M. S., Parisi, J. E., Klos, K. J., & Ahlskog, J. E. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70769-2 · Cited by 267 · see citing works

Biomarker of Neuroinflammation in Parkinson’s Disease

Liu, T.-W., Chen, C., & Chang, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084148 · Cited by 264 · see citing works

Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson’s Disease

More, S. V., Kumar, H., Kim, I. S., Song, S.-Y., & Choi, D.-K. (2013) · Mediators of Inflammation · doi:10.1155/2013/952375 · Cited by 259 · see citing works

Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients

Doorn, K. J., Moors, T., Drukarch, B., van de Berg, W. D., Lucassen, P. J., & van Dam, A.-M. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0090-1 · Cited by 254 · see citing works

Prussian Blue Nanozyme as a Pyroptosis Inhibitor Alleviates Neurodegeneration

Ma, X., Hao, J., Wu, J., Li, Y., Cai, X., & Zheng, Y. (2022) · Advanced Materials · doi:10.1002/adma.202106723 · Cited by 253 · see citing works

First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers

Schenk, D. B., Koller, M., NESS, D. K., Griffith, S. G., Grundman, M., Zago, W. M., Soto, J., Atiee, G. J., Ostrowitzki, S., & Kinney, G. G. (2016) · Movement Disorders · doi:10.1002/mds.26878 · Cited by 248 · see citing works

Neurodegenerative Diseases – Is Metabolic Deficiency the Root Cause?

Muddapu, V. R., Dharshini, S. P., Chakravarthy, V., & Gromiha, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00213 · Cited by 218 · see citing works

Neurological Diseases as Primary Gliopathies: A Reassessment of Neurocentrism

Verkhratsky, A., Sofroniew, M. V., Messing, A., deLanerolle, N. C., Rempe, D. A., Rodriguez, J. J., & Nedergaard, M. (2012) · ASN NEURO · doi:10.1042/an20120010 · Cited by 247 · see citing works

Inflammation and Adaptive Immunity in Parkinson's DiseasePreprint

Mosley, R. L., Hutter-Saunders, J. A. L., Stone, D. K., & Gendelman, H. E. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009381 · Cited by 246 · see citing works

Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases

Lee, M., Cho, T., Jantaratnotai, N., Wang, Y. T., McGeer, E. G., & McGeer, P. L. (2010) · The FASEB Journal · doi:10.1096/fj.09-149997 · Cited by 239 · see citing works

Calcium homeostasis, selective vulnerability and Parkinson's disease

Chan, C. S., Gertler, T. S., & Surmeier, D. J. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.01.006 · Cited by 239 · see citing works

Microglia in the aging brain: relevance to neurodegeneration

Luo, X.-G., Ding, J.-Q., & Chen, S.-D. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-12 · Cited by 236 · see citing works

Inflammation and α-Synuclein’s Prion-like Behavior in Parkinson's Disease—Is There a Link?

Tomé, C. M. L., Tyson, T., Rey, N. L., Grathwohl, S. A., Britschgi, M., & Brundin, P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8267-8 · Cited by 237 · see citing works

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease

Jučaitė, A., Svenningsson, P., Rinne, J. O., Cselényi, Z., Varnäs, K., Johnström, P., Amini, N., Kirjavainen, A. K., Helin, S., Minkwitz, M. C., et al. (2015) · Brain · doi:10.1093/brain/awv184 · Cited by 224 · see citing works

Inhibition of NADPH oxidase promotes alternative and anti‐inflammatory microglial activation during neuroinflammation

Choi, S., Aïd, S., Kim, H., Jackson, S. H., & Bosetti, F. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07572.x · Cited by 222 · see citing works

Ulcerative colitis exacerbates lipopolysaccharide‐induced damage to the nigral dopaminergic system: potential risk factor in Parkinson`s disease

Villarán, R. F., Espinosa‐Oliva, A. M., Soto, M. S., de Pablos, R. M., Argüelles, S., Delgado‐Cortés, M. J., Sobrino, V., van Rooijen, N., Venero, J. L., Herrera, A. J., et al. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06879.x · Cited by 214 · see citing works

Inflammation in the early stages of neurodegenerative pathology

Khandelwal, P. J., Herman, A. M., & Moussa, C. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.07.002 · Cited by 211 · see citing works

Chronic Stress Enhances Microglia Activation and Exacerbates Death of Nigral Dopaminergic Neurons under Conditions of Inflammation

de Pablos, R. M., Herrera, A. J., Espinosa-Oliva, A. M., Sarmiento, M., Muñoz, M. F., Machado, A., & Venero, J. L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-34 · Cited by 201 · see citing works

PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of Parkinson’s disease

Schintu, N., Frau, L., Ibba, M., Caboni, P., Garau, A., Carboni, E., & Carta, A. R. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06657.x · Cited by 200 · see citing works

A Wnt1 regulated Frizzled-1/β-Cateninsignaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection

L’Episcopo, F., Serapide, M. F., Tirolo, C., Testa, N., Caniglia, S., Morale, M. C., Pluchino, S., & Marchetti, B. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-49 · Cited by 196 · see citing works

Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum

Chen, X., Lan, X., Roche, I., Liu, R., & Geiger, J. D. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05697.x · Cited by 189 · see citing works

Akt signal transduction dysfunction in Parkinson's disease

Timmons, S., Coakley, M. F., Moloney, A. M., & Neill, C. O. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.09.055 · Cited by 192 · see citing works

Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

Armentero, M., Pinna, A., Ferré, S., Lanciego, J. L., Müller, C. E., & Franco, R. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.07.004 · Cited by 193 · see citing works

Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson’s disease

Ghosh, A., Tyson, T., George, S., Hildebrandt, E. N., Steiner, J. A., Madaj, Z., Schulz, E., Machiela, E., McDonald, W. G., Galvis, M. L. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2210 · Cited by 187 · see citing works

Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

L’Episcopo, F., Tirolo, C., Testa, N., Caniglia, S., Morale, M. C., Cossetti, C., D’Adamo, P., Zardini, E., Andreoni, L., Ihekwaba, A., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.023 · Cited by 186 · see citing works

Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response

Kan, A. A., van Erp, S., Derijck, A. A. H. A., de Wit, M., Hessel, E. V. S., O’Duibhir, E., de Jager, W., van Rijen, P. C., Gosselaar, P. H., Graan, P. N. E. D., et al. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0992-7 · Cited by 187 · see citing works

Neuron-Astrocyte Interactions in Parkinson’s Disease

Miyazaki, I., & Asanuma, M. (2020) · Cells · doi:10.3390/cells9122623 · Cited by 186 · see citing works

Parkinson's disease, aging and adult neurogenesis: Wnt/β‐catenin signalling as the key to unlock the mystery of endogenous brain repair

Marchetti, B., Tirolo, C., L’Episcopo, F., Caniglia, S., Testa, N., Smith, J. A., Pluchino, S., & Serapide, M. F. (2020) · Aging Cell · doi:10.1111/acel.13101 · Cited by 185 · see citing works

Astrocyte-derived GDNF is a potent inhibitor of microglial activation

Rocha, S. M., Cristóvão, A. C., Campos, F. L., Fonseca, C. P., & Baltazar, G. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.04.014 · Cited by 179 · see citing works

Neuroinflammation in Parkinson’s Disease

Lee, J., Tran, T. A. T., & Tansey, M. G. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9176-0 · Cited by 174 · see citing works

Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair

Vivekanantham, S., Shah, S., Dewji, R., Dewji, A., Khatri, C., & Ologunde, R. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2014.982795 · Cited by 171 · see citing works

Primary Cultures of Astrocytes: Their Value in Understanding Astrocytes in Health and Disease

Lange, S. C., Bak, L. K., Waagepetersen, H. S., Schousboe, A., & Norenberg, M. D. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0868-0 · Cited by 167 · see citing works

β-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease

Ojha, S. K., Javed, H., Azimullah, S., & Haque, M. E. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2733-y · Cited by 165 · see citing works

Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts

Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0833-z · Cited by 162 · see citing works

NSAID Use and the Risk of Parkinsonʼs Disease

Samii, A., Etminan, M., Wiens, M. O., & Jafari, S. (2009) · Drugs & Aging · doi:10.2165/11316780-000000000-00000 · Cited by 161 · see citing works

Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease

Baudrexel, S., Nürnberger, L., Rüb, U., Seifried, C., Klein, J. C., Deller, T., Steinmetz, H., Deichmann, R., & Hilker, R. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.03.005 · Cited by 160 · see citing works

Manganese Induces Dopaminergic Neurodegeneration via Microglial Activation in a Rat Model of Manganism

Zhao, F., Cai, T., Liu, M., Zheng, G., Luo, W., & Chen, J. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn213 · Cited by 157 · see citing works

Glial calcium and diseases of the nervous system

Nedergaard, M., Rodriguez, J. J., & Verkhratsky, A. (2010) · Cell Calcium · doi:10.1016/j.ceca.2009.11.010 · Cited by 159 · see citing works

Glia in the pathogenesis of neurodegenerative diseases

Verkhratsky, A., Parpura, V., Pekna, M., Pekny, M., & Sofroniew, M. V. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140107 · Cited by 157 · see citing works

Pathological α-synuclein exacerbates the progression of Parkinson’s disease through microglial activation

Zhang, Q.-S., Heng, Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2016.11.002 · Cited by 156 · see citing works

Adult neurogenesis in Parkinson’s disease

Marxreiter, F., Regensburger, M., & Winkler, J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1062-x · Cited by 157 · see citing works

Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases

Boyd, R. J., Avramopoulos, D., Jantzie, L. L., & McCallion, A. S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02584-x · Cited by 162 · see citing works

Mitochondria and the Link Between Neuroinflammation and Neurodegeneration

Filippo, M. D., Chiasserini, D., Tozzi, A., Picconi, B., & Calabresi, P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100543 · Cited by 155 · see citing works

Functional dissection of astrocyte-secreted proteins: Implications in brain health and diseases

Jha, M. K., Kim, J.-H., Song, G. J., Lee, W., Lee, I. K., Lee, H., An, S. S. A., Kim, S., & Suk, K. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.003 · Cited by 149 · see citing works

Quercetin and Sesamin Protect Dopaminergic Cells from MPP+-Induced Neuroinflammation in a Microglial (N9)-Neuronal (PC12) Coculture System

Bournival, J., Plouffe, M., Renaud, J., Provencher, C., & Martinoli, M. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/921941 · Cited by 150 · see citing works

Effect of Neuroinflammation on Synaptic Organization and Function in the Developing Brain: Implications for Neurodevelopmental and Neurodegenerative Disorders

Mottahedin, A., Ardalan, M., Chumak, T., Riebe, I., Ek, C. J., & Mallard, C. E. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00190 · Cited by 149 · see citing works

The role of neuroinflammation on the pathogenesis of Parkinson's disease

Chung, Y. C., Ko, H. W., Bok, E., Park, E. S., Huh, S. H., Nam, J. H., & Jin, B. K. (2010) · BMB Reports · doi:10.5483/bmbrep.2010.43.4.225 · Cited by 148 · see citing works

Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease

Esposito, E., Impellizzeri, D., Mazzon, E., Paterniti, I., & Cuzzocrea, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041880 · Cited by 144 · see citing works

What causes cell death in Parkinson's disease?

Gupta, A., Dawson, V. L., & Dawson, T. M. (2009) · Annals of Neurology · doi:10.1002/ana.21573 · Cited by 144 · see citing works

Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration

Henstridge, C. M., Tzioras, M., & Paolicelli, R. C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00063 · Cited by 145 · see citing works

TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson’s diseases in vivo model

Campolo, M., Paterniti, I., Siracusa, R., Filippone, A., Esposito, E., & Cuzzocrea, S. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.12.003 · Cited by 143 · see citing works

Glial Cells as Players in Parkinsonism: The “Good,” the “Bad,” and the “Mysterious” Glia

Mena, M. A., & de Yébenes, J. G. (2008) · The Neuroscientist · doi:10.1177/1073858408322839 · Cited by 141 · see citing works

Astroglia In Neurological Diseases

Verkhratsky, A., Rodríguez, J. J., & Parpura, V. (2013) · Future Neurology · doi:10.2217/fnl.12.90 · Cited by 140 · see citing works

Chronic expression of low levels of tumor necrosis factor-α in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation

Ezcurra, A. L. D. L., Chertoff, M., Ferrari, C. C., Graciarena, M., & Pitossi, F. J. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.018 · Cited by 140 · see citing works

Evidence for angiogenesis in Parkinson’s disease, incidental Lewy body disease, and progressive supranuclear palsy

Desai Bradaric, B., Patel, A., Schneider, J. A., Carvey, P. M., & Hendey, B. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0684-8 · Cited by 139 · see citing works

Methamphetamine Self-Administration Is Associated with Persistent Biochemical Alterations in Striatal and Cortical Dopaminergic Terminals in the Rat

Krasnova, I. N., Justinová, Z., Ladenheim, B., Jayanthi, S., McCoy, M. T., Barnes, C., Warner, J. E., Goldberg, S. R., & Cadet, J. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008790 · Cited by 136 · see citing works

Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model

Carta, A. R., Frau, L., Pisanu, A., Wardas, J., Spiga, S., & Carboni, E. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.07.046 · Cited by 136 · see citing works

The Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease

Baizabal-Carvallo, J. F., & Alonso-Juarez, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.02.030 · Cited by 130 · see citing works

Caffeine Protects Against Disruptions of the Blood-Brain Barrier in Animal Models of Alzheimer's and Parkinson's Diseases

Chen, X., Ghribi, O., & Geiger, J. D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1376 · Cited by 133 · see citing works

Wnt/β-Catenin Signaling Pathway Governs a Full Program for Dopaminergic Neuron Survival, Neurorescue and Regeneration in the MPTP Mouse Model of Parkinson’s Disease

Marchetti, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123743 · Cited by 130 · see citing works

Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson’s disease

Ulusoy, A., Decressac, M., Kirik, D., & Björklund, A. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84005-1 · Cited by 130 · see citing works

Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies

Rees, K., Stowe, R. L., Patel, S., Ives, N. J., Breen, K. C., Clarke, C. E., & Ben‐Shlomo, Y. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454 · Cited by 130 · see citing works

Patterns of medication use by chronic and episodic headache sufferers in the general population: Results from the frequent headache epidemiology study

Scher, I., Lipton, R. B., Stewart, W., & BIGAL, M. E. (2009) · Cephalalgia · doi:10.1111/j.1468-2982.2009.01913.x · Cited by 129 · see citing works

The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis

do Carmo, M. R. S., Menezes, A. P. F., Nunes, A. C. L., Pliássova, A., Rolo, A. P., Palmeira, C. M., Cunha, R. A., Canas, P. M., & de Andrade, G. M. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.01.045 · Cited by 129 · see citing works

Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson’s Disease

Heo, J. Y., Nam, M.-H., Yoon, H. H., Kim, J., Hwang, Y. J., Won, W., Woo, D. H., Lee, J. A., Park, H.-J., Jo, S., et al. (2020) · Current Biology · doi:10.1016/j.cub.2019.11.079 · Cited by 135 · see citing works

Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease

Garrido‐Gil, P., Joglar, B., Rodriguez-Perez, A. I., Guerra, M. J., & Labandeira-García, J. L. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-38 · Cited by 127 · see citing works

Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model

Sarkar, S., Chigurupati, S., Raymick, J. B., Mann, D., Bowyer, J. F., Schmitt, T., Beger, R. D., Hanig, J. P., Schmued, L. C., & Paule, M. G. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.07.006 · Cited by 128 · see citing works

Adenosine A2A Receptors and Parkinson’s Disease

Morelli, M., Carta, A. R., & Jenner, P. G. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_18 · Cited by 125 · see citing works

An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition

Members, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124 · see citing works

Neuroinflammatory processes in Parkinson's disease

Hirsch, É. C., Hunot, S., & Hartmann, A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.013 · Cited by 298 · see citing works

Role of glial cells in neurotoxin-induced animal models of Parkinson’s disease

Yokoyama, H., Uchida, H., Kuroiwa, H., Kasahara, J., & Araki, T. (2010) · Neurological Sciences · doi:10.1007/s10072-010-0424-0 · Cited by 57 · see citing works

The Role of Glial Reaction and Inflammation in Parkinson's Disease

Hirsch, É. C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A., & Michel, P. P. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07478.x · Cited by 449 · see citing works

Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target

Choi, D., & Suk, K. (2007) · Current Signal Transduction Therapy · doi:10.2174/157436207779317146 · Cited by 5 · see citing works

An Inflammatory Pathomechanism for Parkinsons Disease?

Wersinger, C., & Sidhu, A. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776055760 · Cited by 60 · see citing works